GW Pharma (GWPH) Posts Smaller Q4 Loss

GW Pharma (NASDAQ: GWPH) reported Q4 EPS of ($0.07), $0.68 better than the analyst estimate of ($0.75). Revenue for the quarter came in at $109.1 million versus the consensus estimate of $105.1 million.

“2019 was an exceptional and transformative year for GW, led by the successful launch of Epidiolex in the US and approval in Europe. The positive impact this medicine has had on thousands of patients and their families provides a compelling foundation for continued growth in 2020,” said Justin Gover, GW’s Chief Executive Officer. “We also expect 2020 to be an important year for our growing and developing product pipeline beyond Epidiolex as we build on our world leadership in cannabinoid science. We are focused on advancing nabiximols in the US in several indications and clinical programs with other potential products whilst continuing to bring Epidiolex to more patients in the US and Europe.”

For earnings history and earnings-related data on GW Pharma (GWPH) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49